Delivery of miR-320a-3p by gold nanoparticles combined with photothermal therapy for directly targeting Sp1 in lung cancer

2021 ◽  
Author(s):  
Jiefei Peng ◽  
Ranran Wang ◽  
Wanru Sun ◽  
Minhua Huang ◽  
Rong Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Gold Nanoparticles ◽  
Mortality Rate ◽  
Photothermal Therapy ◽  
Therapeutic Targets ◽  
Novel Therapeutic

Lung cancer is the second most common tumor and has the highest mortality rate. Both novel therapeutic targets and approaches are needed to improve the overall survival of patients with...

scholarly journals E2F8 and its target genes as novel therapeutic targets for lung cancer

2016 ◽  
Vol 11 (2) ◽  
pp. S29
Author(s):  
Sin-Aye Park ◽  
Jong Woo Lee ◽  
James Platt ◽  
Joann Sweasy ◽  
Peter Glazer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Target Genes ◽  
Therapeutic Targets ◽  
Novel Therapeutic

Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic

2007 ◽  
Vol 33 (2) ◽  
pp. 203-212 ◽  
Author(s):  
Emma J. Dean ◽  
Malcolm Ranson ◽  
Fiona Blackhall ◽  
Sarah V. Holt ◽  
Caroline Dive
Keyword(s):  
Lung Cancer ◽  
Therapeutic Targets ◽  
Inhibitor Of Apoptosis ◽  
Inhibitor Of Apoptosis Proteins ◽  
Apoptosis Proteins ◽  
Novel Therapeutic

N-cadherin, a potential novel therapeutic target in small cell lung cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 18134-18134
Author(s):  
M. Batus ◽  
K. A. Kaiser ◽  
J. S. Coon ◽  
S. Ahmed ◽  
A. Patel ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Small Cell Lung Cancer ◽  
Treatment Response ◽  
Cell Lung Cancer ◽  
Cyclic Peptide ◽  
Small Cell ◽  
Small Cell Lung ◽  
Response Data ◽  
Novel Therapeutic

18134 Background: New treatment ideas are needed in small cell lung cancer (SCLC). N-cadherin which is associated with increased tumor invasiveness is a potential novel therapeutic target. It seems reasonable to test recently developed cyclic peptide N-cadherin antagonists in tumors with high N-cadherin expression, and it seemed likely that high N-cadherin expression would occur more frequently in aggressive tumors like SCLC. Our objective was to determine the frequency and biological significance of N-cadherin expression in SCLC. Methods: We retrospectively analyzed 86 patients with small cell lung cancer, most of whom received treatment: chemotherapy with or without radiation. We reviewed their clinical charts and obtained: date of diagnosis, age, gender, performance status, treatment dates and treatment response (CR/PR, stable disease, progression), and death or last encounter date. We also analyzed their pathology specimens for frequency of expression of N-cadherin and grouped them into three categories: no expression, some expression of N-cadherin >1% but <35%, and strong expression 36–100%. Subsequently, we determined the correlation between the N-cadherin frequency groups and the overall survival for all 86 patients. We also determined the time to progression in a subset of 56 patients (with available treatment response data). Results: Out of the 86 patients, 18 (21%) did not express N-cadherin, 10 (11.6%) patients showed >1% but <35% expression of N- cadherin, and 58 (67.4%) had a strong expression >36%-100%. There was no association found between N-cadherin expression and overall survival using either the Log-Rank Test or the Wilcoxon Test. In the subset of 56 patients with available treatment response data there was no association between N-cadherin expression and progression free survival. Conclusions: N-cadherin was expressed relatively frequently in this group of SCLC patients, and these results suggest that phase II trials of the novel cyclic peptide N-cadherin antagonists are warranted in SCLC. N-cadherin did not appear to have prognostic value in our study. No significant financial relationships to disclose.

scholarly journals Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

2012 ◽  
Vol 2 (9) ◽  
pp. 798-811 ◽  
Author(s):  
Lauren Averett Byers ◽  
Jing Wang ◽  
Monique B. Nilsson ◽  
Junya Fujimoto ◽  
Pierre Saintigny ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Therapeutic Targets ◽  
Small Cell ◽  
Proteomic Profiling ◽  
Small Cell Lung ◽  
Novel Therapeutic

Novel therapeutic targets in non-small cell lung cancer

2013 ◽  
Vol 13 (3) ◽  
pp. 394-401 ◽  
Author(s):  
Muhammad Alamgeer ◽  
Vinod Ganju ◽  
D Neil Watkins
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Therapeutic Targets ◽  
Small Cell ◽  
Small Cell Lung ◽  
Novel Therapeutic

scholarly journals EGFR Fusions as Novel Therapeutic Targets in Lung Cancer

2016 ◽  
Vol 6 (6) ◽  
pp. 601-611 ◽  
Author(s):  
Kartik Konduri ◽  
Jean-Nicolas Gallant ◽  
Young Kwang Chae ◽  
Francis J. Giles ◽  
Barbara J. Gitlitz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Therapeutic Targets ◽  
Novel Therapeutic

Novel therapeutic targets on the horizon for lung cancer

2016 ◽  
Vol 17 (8) ◽  
pp. e347-e362 ◽  
Author(s):  
Wan-Ling Tan ◽  
Amit Jain ◽  
Angela Takano ◽  
Evan W Newell ◽  
N Gopalakrishna Iyer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Therapeutic Targets ◽  
Novel Therapeutic
Sign in / Sign up

Export Citation Format

Share Document